A 26-year-old antheral who had received palmy cistron therapy for hemophilia B underwent full genu arthroplasty 16 months later, with a origin IX level of 50 IU per deciliter. There was nary excessive bleeding and nary request for further origin IX infusion.
Feng Xue, M.D.
State Key Laboratory of Experimental Hematology, Tianjin, China
PanJing Wang, M.D.
Peking Union Medical College, Beijing, China
Zhen Yuan, M.D.
Chao Shi, M.D.
Shandong Provincial Qianfoshan Hospital, Jinan, China
Yunhai Fang, M.D.
Shandong Blood Center, Jinan, China
Wei Liu, M.D.
Yuhua Wang, M.M.
Blood Diseases Hospital, Tianjin, China
Xiao Xiao, Ph.D.
Belief BioMed, Shanghai, China
Renchi Yang, M.D.
Blood Diseases Hospital, Tianjin, China
Lindsey A. George, M.D.
University of Pennsylvania School of Medicine, Philadelphia, PA
Lei Zhang, M.D.
State Key Laboratory of Experimental Hematology, Tianjin, China
[email protected]
Funding and Disclosures
Supported successful portion by grants from the National Key Research and Development Program of China (2019YFA0110802), the CAMS Innovation Fund for Medical Sciences (2021-I2M-003, 2021-I2M-1-073, and 2022-I2M-2-001), the Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences (2020-PT310-011), and the Bayer Hemophilia Award Program (2021).
Disclosure forms provided by the authors are disposable with the afloat substance of this missive astatine NEJM.org.
Drs. Xue, P. Wang, and Yuan contributed arsenic to this letter.
English (US)